Theriva Biologics, Inc. (TOVX) Stock Price & Analysis
Theriva Biologics, Inc. (TOVX) fell 6.68% to USD 0.24 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.
TOVX last closed at USD 0.26; the session ranged USD 0.23–0.26 on volume of 1,389,773 shares. Market capitalization is $11.09M, with a 52-week range of USD 0.16–0.86 (ASE). Source: Nexqual, June 10, 2026 at 02:21 UTC.
Key Statistics (as of June 10, 2026 at 02:21 UTC)
| Price | USD 0.24 |
|---|---|
| Change | ▼ 6.68% (down) |
| Previous Close | USD 0.26 |
| Open | USD 0.26 |
| Day Range | USD 0.23 – 0.26 |
| 52-Week Range | USD 0.16 – 0.86 |
| Volume | 1,389,773 shares |
| Market Cap | $11.09M |
| Exchange | ASE |
Technical Analysis (TOVX)
Nexqual's technical model rates TOVX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.06 (neutral) |
| vs SMA50 | Below (USD 0.3) |
| MACD | -0.01 (negative) |
Analyst Ratings (TOVX)
Wall Street analysts rate TOVX "None" based on 2 analysts, with a mean price target of USD 2.5 (range USD 1–4), per Nexqual as of June 10, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 2.5 |
| High Target | USD 4 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (TOVX)
| EPS Estimate | USD -0.05 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.05 ▲ beat |
| 2025-09-30 | USD -0.45 vs est -0.38 ▼ miss |
| 2025-06-30 | USD -1.93 vs est -0.47 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financials & Fundamentals (TOVX)
| Total Revenue | $300,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -709.00% |
| Profit Margin | +0.00% |
| ROE | -138.91% |
| Debt / Equity | 23.98 |
| Current Ratio | 1.63 |
| Total Cash | $14.43M |
| Total Debt | $3.69M |
| Free Cash Flow | $-4.87M |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financial Health Score (TOVX)
Nexqual rates Theriva Biologics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $14M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$14M |
| Efficiency | Critical — ROE -139%, ROA -22.6% |
Ownership (TOVX)
| Insider Ownership | +1.70% |
|---|---|
| Institutional Ownership | +4.32% |
| Shares Outstanding | 45.89M |
| Float | 45.14M |
| Short % of Float | +5.94% |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Leadership (TOVX)
Theriva Biologics, Inc. is led by Steven A. Shallcross (age 64), CEO, CFO, Treasurer, Corporate Secretary & Director, per Nexqual as of June 10, 2026 at 02:21 UTC.
| CEO, CFO, Treasurer, Corporate Secretary & Director | Steven A. Shallcross (age 64) |
|---|---|
| Senior Vice President of Corporate & Product Development | Vince Wacher |
| Senior Vice President of Discovery | Ramon Alemany |
Major Backers & Investors (TOVX)
Notable institutional backers of Theriva Biologics, Inc. include Fidelity, Virtu Financial LLC, UBS Group AG, according to Nexqual as of June 10, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.94% |
| Virtu Financial LLC | 0.55% |
| UBS Group AG | 0.49% |
| Jane Street Group, LLC | 0.39% |
| Ikarian Capital, LLC | 0.24% |
| Two Sigma Securities, LLC | 0.23% |
| Xtx Topco Ltd | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.37% |
| Geode Capital | 0.98% |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
From Theriva Biologics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
- Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
- The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.
- In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CMND | Clearmind Medicine Inc. | USD 3.39 | ▼ 14.82% |
| AZTR | Azitra Inc | USD 0.21 | ▲ 0.62% |
| BENF | Beneficient | USD 3.44 | ▼ 2.82% |
| MGRX | Mangoceuticals, Inc. | USD 0.34 | ▼ 4.48% |
| VRAX | Virax Biolabs Group Limited | USD 0.19 | ▼ 11.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.